About Pulmonx
Pulmonx is a publicly listed company based in Redwood City (United States) founded in 1998. Developer of smart devices for treating pulmonary diseases. Pulmonx has raised $280.91 million across 15 funding rounds from investors including Canadian Imperial Bank of Commerce, Kleiner Perkins and RTW Investments. The company has 291 employees. Pulmonx has completed 2 acquisitions, including Aeris Therapeutics and Emphasys Medical. Its chief executive, as recorded, is Glen French. Its website pulmonx.com draws about 12 thousand monthly visits. Pulmonx offers products and services including Zephyr Valves, Chartis System, and StratX Reports. Its focus areas include Life Sciences, Pulmonology, Medical Devices and Therapeutic Devices. Its legal entity is Pulmonx Corporation. Its competitors include Spiration, Uptake Medical and Emphasys Medical; 3 of its 3 listed competitors have raised funding.
Company details
Pulmonx is a developer of smart devices for treating pulmonary diseases. The company is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. It is currently engaged in the design, development, and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The companys Zephyr Endobronchial Valve (EBV) therapy involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The company has a CE Mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System.
- Annual Revenue$90.5 M (USD)8.01as on Dec 31, 2025
- Net Profit-$54 M (USD)4.24as on Dec 31, 2025
- EBITDA-$52.51 M (USD)3.47as on Dec 31, 2025
- Total Equity Funding$280.91M (USD)
in 15 rounds
- Latest Funding Round$66M (USD), Series D
May 2020
- InvestorsCanadian Imperial Bank of Commerce
& 15 more
- Employee Count291
- Investments & AcquisitionsAeris Therapeutics
& 1 more
Products & Services of Pulmonx
Pulmonx offers a comprehensive portfolio of products and services, including Zephyr Valves, Chartis System, and StratX Reports.
Device for treating severe COPD by reducing hyperinflation.
System for assessing patients' pulmonary function.
Reports for evaluating CT scans in COPD treatment.
Apps and channels of Pulmonx
its YouTube channel Zephyr by Pulmonx has 2.32K subscribers and 30 videos.
Videos from Pulmonx
The most watched videos on Pulmonx's YouTube channel, Zephyr by Pulmonx (2.32K subscribers). Click a video to play it here.
More on Zephyr by Pulmonx.
Funding Insights of Pulmonx
Pulmonx has successfully raised a total of $280.91M across 15 strategic funding rounds. The most recent funding activity was a Series D round of $66 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $280.91M
- Total Rounds 15
- Last Round Series D — $66M
- First Round $7.06M
(Dec 2003)
- Investors Count 16
Latest 10 of 15 funding rounds of Pulmonx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $17M | Debt – Conventional | – | – | |
| May 2020 | $66M | Series D | – | Ally Bridge Group | |
| Apr 2019 | $65.13M | Series D | – | Ally Bridge Group | |
| Mar 2017 | $50M | Series D | – | – | – |
| Sep 2014 | $20M | Debt – Conventional | – | – | |
| Apr 2014 | $10M | Series C | – | – | – |
| Feb 2012 | $10M | Series C | – | – | – |
| Apr 2010 | $33.59M | Series C | – | Healthcap, Kleiner Perkins | |
| Jan 2010 | $11.53M | Series C | – | – | – |
| Apr 2009 | $2.86M | Series B | – | – | – |
16 investors in total: 16 institutional.
Investors in Pulmonx
Pulmonx has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Canadian Imperial Bank of Commerce, Kleiner Perkins and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on tech and life sciences startups. | healthquestcapital.com | Belmont, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
Healthcare companies are invested in by this private equity firm. | pfmhealthsciences.com | San Francisco, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
| denovovc.com | ||||
Early-stage healthcare startups are supported with venture capital. | lvpcapital.com | San Ramon, United States | ||
Life sciences sector focused VC firm funding companies in the US | medven.com | Emeryville, United States | ||
| healthcap.eu |
Investor details for Pulmonx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pulmonx
115 people are tracked at Pulmonx (37 in leadership, 7 in board & advisors, 71 in team); the tracked headcount is 291.
| Name | Role | Group |
|---|---|---|
Glen French | CEO | Leadership |
Bryan Hix | Vice President Of Commercial Operations | Leadership |
Lauren Cristina | VP, Finance & Administration (U.S.) | Leadership |
Glendon E. French | President & CEO | Leadership |
Jérôme Erath | SVP & General Manager, Europe, the Middle East & Africa | Leadership |
Narinder S. Shargill | VP, Global Medical Affairs | Leadership |
Nick Woodcock | Area Vice President Of Sales, EMEA | Leadership |
Beran Rose | Chief Commercial Officer | Leadership |
Sri Radhakrishnan | Chief Technical Officer | Leadership |
Conor McGuire | Regional Business Director | Leadership |
Tanner Johnson | Senior Regional Business Director | Leadership |
Lisa Paul | Chief People Officer | Leadership |
Marcee Maroney | VP, Marketing | Leadership |
Peter Svensson | VP Sales | Leadership |
Antony Kurumundayil | Sales Director Germany | Leadership |
Jeff W. | Sr. Director Information Technology | Leadership |
Marilyn Cornelious | Director, Human Resources | Leadership |
Jim Bobbitt | Regional Business Director | Leadership |
Martin Schneider | VP Finance, CFO International | Leadership |
Steve Wallace P.e. | Director Of Operations | Leadership |
95 more people are available in the full profile.
Complete people profiles for Pulmonx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Pulmonx
Pulmonx is a publicly listed company on the NASDAQ with ticker symbol LUNG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Oct 2020
- Listed onNASDAQ: LUNG
- Listed entityPulmonx Corporation
- Exchange sectorHealth technology
- ISINUS7458481014
- Share price$1.76 (-2.22% on the day) · 2026-10-13
- Market capitalisation$75.6M
- EPS (diluted, trailing year)$-1.16
- Volume (last session)498,611
Financials of Pulmonx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $90.5M | -$54.0M | -$52.5M |
| 2024 | $83.8M | -$56.4M | -$54.4M |
| 2023 | $68.7M | -$60.8M | -$60.0M |
| 2022 | $53.7M | -$58.9M | -$54.6M |
| 2021 | $48.4M | -$48.7M | -$44.1M |
Detailed financial statements for Pulmonx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pulmonx
Pulmonx has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aeris Therapeutics and Emphasys Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Products for treating emphysema and lung diseases are developed. | aerist.com | Woburn, United States | 2000 | Jan 2015 | •••• | |
Endobronchial valves for emphysema treatment are developed. | emphasysmedical.com | Redwood, United States | 2000 | May 2009 | •••• |
Complete acquisition details for Pulmonx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pulmonx
6 dated milestones of Pulmonx across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Pulmonx is founded.
- Funding First funding round of $7.1M.
- Acquisition Acquires Emphasys Medical.
- Acquisition Acquires Aeris Therapeutics.
- Funding Latest funding round, Series D, of $66.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Pulmonx
Pulmonx has 3 listed competitors in our database, 3 of them funded. They include Spiration, Uptake Medical and Emphasys Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| spiration.com | 1999 | Redmond, United States | $73.9M | 74 | IntraBronchial Valve to treat lung disease | |
| uptakemedical.com | 2005 | Tustin, United States | $71.68M | Targeted vapor therapy is developed for endoscopic lung volume reduction. | ||
| emphasysmedical.com | 2000 | Redwood, United States | $68.4M | Endobronchial valves for emphysema treatment are developed. |
Detailed competitors of Pulmonx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pulmonx
The website of Pulmonx (pulmonx.com) receives about 12.2K visits a month.
- Monthly visits12.2K
▼ 23.7% vs previous month
Websites whose visitors overlap most with Pulmonx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
beckersasc.com | beckersasc.com | 100% | #370,957 | – | |
roche.ch | roche.ch | 72% | #1,273,167 | – | |
consulentiolistici.it | consulentiolistici.it | 62% | – | ||
mkkliniken.de | mkkliniken.de | 60% | #770,356 | – | |
lesouffle.org | lesouffle.org | 60% | #1,038,373 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Pulmonx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as Pulmonx (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pulmonx
Complete news archive for Pulmonx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pulmonx
Pulmonx was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Pulmonx is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Glen French is the CEO of Pulmonx, as recorded in our data.
Pulmonx is a funded company, having raised a total of $280.91M across 15 funding rounds to date. The company's 1st funding round was a Series B of $2.86M, raised on Dec 2003.
Pulmonx has 291 employees.
Annual revenue of Pulmonx is $90.5M as on Dec 31, 2025.
Pulmonx is a developer of smart devices for treating pulmonary diseases. The company is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. It is currently engaged in the design, development, and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The companys Zephyr Endobronchial Valve (EBV) therapy involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The company has a CE Mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System.
Pulmonx's top competitors include Spiration, Uptake Medical and Emphasys Medical.
Pulmonx offers Zephyr Valves, Chartis System, and StratX Reports.
Yes, Pulmonx is publicly traded on NASDAQ under the ticker symbol LUNG.
Pulmonx has made 2 acquisitions, including Aeris Therapeutics, and Emphasys Medical.
Pulmonx has 16 investors. Key investors include Canadian Imperial Bank of Commerce, Kleiner Perkins, RTW Investments, Driehaus, and Oxford Finance.